Get the Stockscreener App
52.47
2.82%
-1.52
Pre-market:
53.39
0.92
+1.75%
Haemonetics Corp stock is traded at $52.47, with a volume of 1.34M.
It is down -2.82% in the last 24 hours and down -30.52% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$53.99
Open:
$53.8
24h Volume:
1.34M
Relative Volume:
1.97
Market Cap:
$2.53B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
21.77
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-31.23%
1M Performance:
-30.52%
6M Performance:
-14.74%
1Y Performance:
-31.88%
1-Day Range:
$52.29
$54.78
1-Week Range:
$52.29
$76.84
52-Week Range:
$52.29
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
52.47 | 2.60B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Is Haemonetics Corporation meeting your algorithmic filter criteriaDaily Investment Ideas with Market Insight - Newser
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE) - Seeking Alpha
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown - Investing.com
Haemonetics’ (HAE) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Mizuho Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Haemonetics Corporation stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Needham & Company LLC Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Barrington Research Lowers Haemonetics (NYSE:HAE) Price Target to $86.00 - Defense World
Haemonetics’ (HAE) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $62 to $86 - 富途牛牛
Detecting price anomalies in Haemonetics Corporation with AIFree Trade Ready Stock Watch for Short Term - Newser
What makes Haemonetics Corporation stock price move sharplyAI Swing Strategy Signal Forecasting System - Newser
How to escape a deep drawdown in Haemonetics CorporationBuy Point Strategy with Profit Protection - Newser
Haemonetics Reports Q1 Fiscal 2026 Earnings - The Globe and Mail
Haemonetics Corporation stock trendline breakdownFree Breakout Confirmation With Entry Tracker - Newser
Haemonetics Corp Reports Strong Organic Growth Despite Portfolio Transitions - AInvest
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Benzinga
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Technical signs of recovery in Haemonetics CorporationSummary of Consistent Growth Stock Picks - Newser
Haemonetics: Fiscal Q1 Earnings Snapshot - Connecticut Post
Haemonetics stock rating cut by JPMorgan on mixed results - Investing.com
Haemonetics (NYSE:HAE) Shares Down 22.1% Following Analyst Downgrade - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Corp (HAE) Analysts Lower Price Target to $68, Maintain "Buy" Rating - AInvest
Analyst Needham Lowers Price Target for Haemonetics (HAE) to $68 - GuruFocus
Haemonetics stock price target lowered to $68 at Needham on competition - Investing.com Canada
Earnings call transcript: Haemonetics beats Q1 2026 earnings, stock drops - Investing.com
Haemonetics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say - Nasdaq
Haemonetics Corporation Reports Earnings Results for the First Quarter Ended June 28, 2025 - MarketScreener
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Haemonetics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Haemonetics (HAE) Q1 Revenue Falls 4% - The Motley Fool
Haemonetics Corp Q1 Fiscal 2026 Earnings: Revenue Surpasses Esti - GuruFocus
Haemonetics' Q1 2025 Earnings: Strategic Resilience and Long-Term Value Amid Plasma Challenges - AInvest
Haemonetics Corporation Q1 Fiscal 2026 Results - TradingView
HAEMONETICS CORP SEC 10-Q Report - TradingView
Haemonetics Q1 FY26 Earnings Released Today: Join Live Conference Call for Full Analysis - Stock Titan
Is Haemonetics Corporation stock entering bullish territoryFree Buy Signal Based on Chart Analysis - Newser
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
What makes Haemonetics Corporation stock attractive to long term investorsCapital Protection Strategy With Risk Analysis - Newser
Brokerages Set Haemonetics Corporation (NYSE:HAE) Price Target at $97.30 - Defense World
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Why Haemonetics Corporation stock attracts strong analyst attentionCapital Safe Picks with Consistent Gains - Newser
Analyzing net buyer seller activity in Haemonetics CorporationDownside Control Plan With Support Analysis - Newser
Using data models to predict Haemonetics Corporation stock movementAccurate Forecast System with AI Support - Newser
Leading vs lagging indicators on Haemonetics Corporation performanceFree Chart Driven High Reward Trading Setup - Newser
What drives Haemonetics Corporation stock priceCapitalize on market trends with confidence - Jammu Links News
What analysts say about Haemonetics Corporation stockCapitalize on emerging market trends - Jammu Links News
Should you hold or exit Haemonetics Corporation nowFree High Growth Low Risk Stock Selection - Newser
Should I hold or sell Haemonetics Corporation stock in 2025Get timely advice on market trends - Jammu Links News
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):